Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Oncogene - 3 Feb 2011

Dunn E F, Iida M, Myers R A, Campbell D A, Hintz K A, Armstrong E A, Li C, Wheeler D L

Abstract excerpt

KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs). We analyzed 16 CRC lines for: (1) KRAS mutation status, (2)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Caco-2 Cells
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Drug Synergism

Share to HCT116 Cells

Share to src-Family Kinases

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 20956938
DOI: 10.1038/onc.2010.430
PMCID: PMC3025039

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.PMID 20956938Read ↗

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancerSemantic proximity Read ↗

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.Semantic proximity Read ↗

Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.Semantic proximity Read ↗

Targeting the PI3K signaling pathway in KRAS mutant colon cancer.Semantic proximity Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.Semantic proximity Read ↗

Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.Semantic proximity Read ↗

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.Semantic proximity Read ↗

Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.Semantic proximity Read ↗

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximabSemantic proximity Read ↗

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Semantic proximity Read ↗

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.